Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

e (aPTT). The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in an average ACT per subject ranging from 373 to 414 seconds and an increase of approximately three times baseline. Average PT values per subject ranged from 56 to 92 seconds and had an increase of approximately five times baseline. Average aPTT values per subject ranged from 130 to 178 seconds and had an increase of approximately five times baseline. All measurements were maintained stably throughout the four-hour infusion. Once the infusion ended, the ACT and other coagulation parameters showed a rapid return toward baseline, consistent with the short plasma half-life of NU172 observed in the Phase 1a trial. In addition, NU172 was well-tolerated with no serious adverse events.

"In this study, we were able to identify a dose that meets or exceeds the level of anticoagulation needed for the indications we plan to evaluate, including CABG surgery," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "In addition to supporting our previous proof-of-concept data, the Phase 1b study shows that anticoagulation with NU172 can be maintained for four hours, which is longer than a typical CABG procedure. We are on track to launch a Phase 2 study evaluating NU172 in the fourth quarter of 2008 or the first quarter of 2009."

Approximately 450,000 CABG procedures, 50 million dialysis procedures, and 1.2 million PCIs are performed annually in the U.S. During these procedures, anticoagulants are given to prevent blood clotting. In CABG procedures and often in dialysis, the anticoagulation effect of heparin must be reversed with protamine once the procedure has been completed.

About Aptamers and NU172

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and a
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... the Morgan Stanley Healthcare conference on Tuesday, September ... Huennekens , president and chief executive officer, will ...
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... corporate and clinical activities at the company ... ongoing clinical trials and future clinical development ... Executive Officer Robert Hershberg , M.D., ...
(Date:9/2/2014)... Sept. 2, 2014  VentiRx Pharmaceuticals, Inc., ... the development and commercialization of novel Toll-like ... the U.S. Food and Drug Administration (FDA) ... investigation of motolimod (VTX-2337) when administered in ... the treatment of women with ovarian cancer ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... May 20, 2011 Neuland Laboratories Ltd., (NSE:NEULANDLAB; BOM:524558) ... intermediates, and contract research and manufacturing services to customers ... the 2011 fiscal year (FY) ended March 31, 2011. ... in fiscal year 2011, Neuland delivered on our commitment ...
... Winner Medical Group Inc. (Nasdaq: WWIN ; ... medical dressings, medical disposables and non-woven fabric made from ... that its PurCotton Industrial Wipes was nominated one of ... Award™. The Company will compete with the ...
Cached Medicine Technology:Neuland Labs Reports Financial Results for Fiscal Year 2011 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 2Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 3Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM) 4
(Date:9/2/2014)... 2014 The global market for peripheral ... by 2020, growing at an estimated CAGR of 7.2% ... by Grand View Research, Inc. Peripheral vascular devices such ... are used for treating peripheral arterial or coronary arterial ... in arteries. These devices are used to decrease the ...
(Date:9/2/2014)... Eric Jimenez and Leah Ashley announced today ... makeup application device. Designed to improve and accelerate makeup ... palm of women’s hands to help them get flawless ... success lies in its patented technology. With a battery-operated ... pulses per minute, the device applies foundation evenly in ...
(Date:9/2/2014)... BESLER Consulting, a leading provider of ... pleased to announce that it has released a special ... FY 2015 Hospital Inpatient Prospective Payment System (IPPS) final ... Medicaid Services. , “Hospitals are facing decreased Medicare reimbursements ... Besler, BESLER’s President and Chief Executive Officer. “We are ...
(Date:9/2/2014)... 02, 2014 At the world-famous Magic Castle ... the unique distinction of being the first and only female ... Lee is the first female magician to hold such a ... at the Magic Castle,” says Misty Lee. “Even since I ... the Magic Castle, I can fascinate guests in much the ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
Breaking Medicine News(10 mins):Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3
... are struggling with the health fallout caused by a lack ... Most women don,t need a survey to tell them a ... too sluggish to make it through the day with vigor. ... moms, empty-nesters or grandmothers, many -- if not most -- ...
... under 80, could ease expected worldwide shortfall of supplies , , ... called HBOC-201 proved safe and effective in a six-week Phase ... In all, 688 patients, ages 18 and older, who had ... (about one pint) or an equivalent one unit (65 grams) ...
... 20 The United States,has provided $50,000 in ... to assist people affected by the food,shortages in ... emerged in recent months because the flowering of ... rat infestations in,crop-growing areas. With funds provided by ...
... of,Agriculture is recommending that consumers who have purchased raw ... County, discard it immediately,due to the risk of Listeria ... milk is milk that has not been pasteurized or ... requires they obtain,permits and be inspected to reduce health ...
... Tenn., June 20 TeamHealth announced today,that Heidi S. ... counsel, reporting directly to the CEO. Ms. Allen is ... retire on July 31,2008, after nine years with TeamHealth., ... a member of TeamHealth,s senior,management team, working with all ...
... shows , , FRIDAY, June 20 (HealthDay News) -- Measles may ... world, but new research shows that it does not spread ... believed. , Mayo Clinic researchers, whose work was published ... of Clinical Investigation , reported that the measles virus instead ...
Cached Medicine News:Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:PA Agriculture Department Warns Consumers About Raw Milk Sold by York County Dairy 2Health News:TeamHealth Announces Appointment of Heidi Allen as Senior Vice President and General Counsel 2Health News:Measle's Spread Doesn't Depend on Airways 2
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: When high buckle is required. Overall length: 14.0 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
Medicine Products: